Abstract

GALEANO, Martha Sady et al. Experience in the demyelinating diseases unit after 2 years. An. Fac. Cienc. Méd. (Asunción) [online]. 2021, vol.54, n.3, pp.113-118. ISSN 1816-8949.  https://doi.org/10.18004/anales/2021.054.03.113.

Multiple sclerosis is a chronic demyelinating disease that causes progressive disability, so treatment focuses on slowing progression, preventing relapses, and effectively reducing symptoms. We conducted an observational, descriptive, longitudinal, single-center study with patients admitted to the demyelinating diseases unit from December 2017 to February 2020. Of the total number of patients, 62.5% received treatment with ocrelizumab and completed 12-month follow-up, without disease progression. With this study, we highlight the importance and effectiveness of disease-modifying treatments.

Keywords : Demielinating Diseases; Multiple Sclerosis; Ocrelizumab; Remiting-Relapsing Multiple Sclerosis; Primary Progressive Multiple Sclerosis..

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )